Starbucks has confirmed it will end coverage of GLP-1 weight loss drugs for employees, joining a growing list of companies pulling back from a benefit that has become far more expensive than expected. The decision lands the same week Novo Nordisk shifted its advertising business to a new agency, a sign of how much money is now riding on these drugs. For readers who rely on employer coverage, the trend is worth watching closely, since it may affect what you pay out of pocket in the months ahead.
The decision comes as more large employers reconsider GLP-1 coverage, since the price tag for these drugs is straining health plans nationwide. It affects employees who had relied on the benefit to help cover the cost of medications like Wegovy or Zepbound, which can run over a thousand dollars a month without insurance. Employers across industries are facing similar pressure, since the number of workers seeking these prescriptions has grown quickly and shows no sign of slowing. For Starbucks employees who use or were considering these medications, the change means a harder look at other coverage options, including manufacturer savings programs or a different insurance plan through a spouse or partner.
Losing this account represents one of the larger shifts in pharmaceutical advertising this year, since WPP had held the business and now moves aside for Omnicom. The size of the account, valued at $520 million, reflects how central marketing has become to Novo Nordisk's strategy as competition from Eli Lilly and other manufacturers intensifies. Winning this business gives Omnicom a substantial and visible piece of pharmaceutical advertising at a moment when GLP-1 drugs are among the most talked about products in the country. For a company the size of Novo Nordisk, this kind of account change often signals a broader push to reach new audiences or refine its message as the market for these drugs shifts.
This shift often catches people off guard, since appetite suppression was the expected effect of these drugs, not a redirection of interest toward something new and often costly. Some users describe spending more on this new pursuit than they used to spend on food itself, which raises its own budgeting questions alongside the cost of the medication. The change appears widely reported among people using GLP-1s, suggesting it is not an isolated experience but a pattern worth paying attention to. If you are on a GLP-1 and notice a similar shift in what interests you, it may help to plan for the added expense the same way you would plan for the cost of the prescription itself.
The column takes shape as an ongoing, personal record rather than a guide, following one contributor through the experience of microdosing GLP-1 drugs. It offers a first-person account rather than instructions for readers to follow themselves, since the writer's approach falls outside standard prescribing guidance. The debut entry joins the site's broader coverage of how people are experimenting with lower doses for reasons ranging from cost to side effect management. Readers interested in a personal perspective on this kind of experimentation can follow the column as new entries are published.
None of this changes what you should do if you are currently on a GLP-1 or considering one. If you get coverage through your employer, it is a good time to check whether that benefit is at risk of changing next year, so you are not caught without a plan. And if you notice new habits or spending patterns since starting the medication, it may be worth talking through with your doctor or your budget, whichever needs the attention first.
Key details
Starbucks is dropping GLP-1 weight loss coverage as employers retreat from the benefit.
Omnicom won Novo Nordisk's $520 million U.S. media account, beating WPP.
Many GLP-1 users say food no longer excites them, replaced by a new, pricey obsession.
A new column launches with one writer's account of microdosing GLP-1 drugs.
Sources
Omnicom Wins U.S. Media Account for Ozempic and Wegovy Maker Novo Nordisk — Adweek
People On GLP-1s Say They Suddenly Have This 1 Unexpected Obsession — HuffPost
Goodman: I started micro-dosing GLP-1 and here’s what happened — AL.com